Effectiveness of Regdanvimab and Remdesivir in Patients with COVID-19 at a Single Hospital
Author:
Affiliation:
1. Department ofFamily Medicine, H Plus Yangji Hospital, Seoul, Korea
2. Department ofInfectious Disease, H Plus Yangji Hospital, Seoul, Korea
Publisher
The Korean Academy of Family Medicine
Subject
General Earth and Planetary Sciences,General Engineering,General Environmental Science
Link
http://pdf.medrang.co.kr/KJFP2/2022/012/KJFP012-05-340.pdf
Reference20 articles.
1. WHO. WHO coronavirus (COVID-19) dashboard [Internet]. Geneva: WHO [cited 2022 May 31]. Available from: https://covid19.who.int/.
2. Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study
3. Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis
4. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
5. Celltrion. Celltrions monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS) 2021 [Internet]. Incheon: Celltrion Healthcare Co.; 2021 [cited 2022 May 31]. Available from: http://www.celltrionhealthcare.com.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3